{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:13:59Z","timestamp":1759342439463},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T00:00:00Z","timestamp":1384992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00005-013-0262-x","type":"journal-article","created":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T06:50:17Z","timestamp":1384930217000},"page":"59-66","source":"Crossref","is-referenced-by-count":7,"title":["Intranasal Administration of Perillyl Alcohol Activates Peripheral and Bronchus-Associated Immune System In Vivo"],"prefix":"10.2478","volume":"62","author":[{"given":"Marcela","family":"D\u2019Alincourt Salazar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Ferreira","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clovis Orlando","family":"Da Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussara","family":"Lagrota-Candido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thereza","family":"Quirico-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2013,11,21]]},"reference":[{"key":"262_CR1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-003-0599-7","volume":"51","author":"CG Azzoli","year":"2003","unstructured":"Azzoli CG, Miller VA, Ng KK et al (2003) A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 51:493\u2013498","journal-title":"Cancer Chemother Pharmacol"},{"key":"262_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00280-004-0788-z","volume":"54","author":"HH Bailey","year":"2004","unstructured":"Bailey HH, Wilding G, Tutsch KD et al (2004) A phase I trial of perillyl alcohol administered four times daily for 14\u00a0days out of 28\u00a0days. Cancer Chemother Pharmacol 54:368\u2013376","journal-title":"Cancer Chemother Pharmacol"},{"key":"262_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/10611860802382777","volume":"17","author":"WA Banks","year":"2009","unstructured":"Banks WA, Morley JE, Niehoff ML et al (2009) Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target 17:91\u201397","journal-title":"J Drug Target"},{"key":"262_CR4","first-page":"448","volume":"3","author":"JT Belanger","year":"1998","unstructured":"Belanger JT (1998) Perillyl alcohol: applications in oncology. Altern Med Rev 3:448\u2013457","journal-title":"Altern Med Rev"},{"key":"262_CR5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.nano.2011.02.008","volume":"7","author":"G Caruso","year":"2011","unstructured":"Caruso G, Caffo M, Alafaci C et al (2011) Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomedicine 7:744\u2013752","journal-title":"Nanomedicine"},{"key":"262_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cbi.2008.12.016","volume":"179","author":"SC Chaudhary","year":"2009","unstructured":"Chaudhary SC, Alam MS, Siddiqui MS et al (2009) Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 179:145\u2013153","journal-title":"Chem Biol Interact"},{"key":"262_CR7","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1158\/1535-7163.MCT-12-0321","volume":"11","author":"H-Y Cho","year":"2012","unstructured":"Cho H-Y, Wang W, Jhaveri N et al (2012) Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 11:2462\u20132472","journal-title":"Mol Cancer Ther"},{"key":"262_CR8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(94)90341-7","volume":"47","author":"PL Crowell","year":"1994","unstructured":"Crowell PL, Ren Z, Lin S et al (1994) Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47:1405\u20131415","journal-title":"Biochem Pharmacol"},{"key":"262_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00005-008-0027-0","volume":"56","author":"CO Fonseca da","year":"2008","unstructured":"da Fonseca CO, Linden R, Futuro D et al (2008a) Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp 56:267\u2013276","journal-title":"Arch Immunol Ther Exp"},{"key":"262_CR10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.surneu.2007.07.040","volume":"70","author":"CO Fonseca da","year":"2008","unstructured":"da Fonseca CO, Schwartsmann G, Fischer J et al (2008b) Preliminary results from a phase I\/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70:259\u2013266","journal-title":"Surg Neurol"},{"key":"262_CR11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00432-010-0873-0","volume":"137","author":"CO Fonseca da","year":"2011","unstructured":"da Fonseca CO, Simao M, Lins IR et al (2011a) Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137:287\u2013293","journal-title":"J Cancer Res Clin Oncol"},{"key":"262_CR12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4236\/jct.2011.21003","volume":"2","author":"CO Fonseca da","year":"2011","unstructured":"da Fonseca CO, Teixeira RM, Ramina R et al (2011b) Case of advanced recurrent glioblastoma successfully treated with monoterpene perillyl alcohol by intranasal administration. J Cancer Ther 2:16\u201321","journal-title":"J Cancer Ther"},{"key":"262_CR13","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.tetlet.2010.01.003","volume":"51","author":"CB Das","year":"2010","unstructured":"Das CB, Mahlingam SM, Panda L et al (2010) Design and synthesis of potential new apoptosis agents: hybrid compounds containing perillyl alcohol and new constrained retinoids. Tetrahedron Lett 51:1462\u20131466","journal-title":"Tetrahedron Lett"},{"key":"262_CR14","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria SV, Hanson LR, Frey WH (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99:1654\u20131673","journal-title":"J Pharm Sci"},{"key":"262_CR15","first-page":"4021","volume":"52","author":"JD Haag","year":"1992","unstructured":"Haag JD, Lindstrom MJ, Gould MN (1992) Limonene-induced regression of mammary carcinomas. Cancer Res 52:4021\u20134026","journal-title":"Cancer Res"},{"key":"262_CR16","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.270.29.17508","volume":"270","author":"RJ Hohl","year":"1995","unstructured":"Hohl RJ, Lewis K (1995) Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270:17508\u201317512","journal-title":"J Biol Chem"},{"key":"262_CR17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1194\/jlr.M300057-JLR200","volume":"44","author":"SA Holstein","year":"2003","unstructured":"Holstein SA, Hohl RJ (2003) Monoterpene regulation of Ras and Ras-related protein expression. J Lipid Res 44:1209\u20131215","journal-title":"J Lipid Res"},{"key":"262_CR18","first-page":"3071","volume":"6","author":"GR Hudes","year":"2000","unstructured":"Hudes GR, Szarka CE, Adams A et al (2000) Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6:3071\u20133080","journal-title":"Clin Cancer Res"},{"key":"262_CR19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.104.070516","volume":"311","author":"H Loutrari","year":"2004","unstructured":"Loutrari H, Hatziapostolou M, Skouridou V et al (2004) Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 311:568\u2013575","journal-title":"J Pharmacol Exp Ther"},{"key":"262_CR20","doi-asserted-by":"crossref","first-page":"35968","DOI":"10.1074\/jbc.M303280200","volume":"278","author":"D Rajesh","year":"2003","unstructured":"Rajesh D, Stenzel RA, Howard SP (2003) Perillyl alcohol as a radio-\/chemosensitizer in malignant glioma. J Biol Chem 278:35968\u201335978","journal-title":"J Biol Chem"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-013-0262-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00005-013-0262-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-013-0262-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:48:01Z","timestamp":1704228481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00005-013-0262-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,21]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s00005-013-0262-x","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,21]]}}}